



**ASX ANNOUNCEMENT**

**14 December 2017**

## **Cynata Receives \$1.3m R&D Tax Incentive Refund**

**Melbourne, Australia; 14 December 2017:** Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the Company has received a A\$1,328,649 R&D Tax Incentive Refund for the 2016/2017 financial year.

The Tax Incentive Refund further bolsters the Company's cash position and extends its operating runway into 2019 based on current projections. The Company is well funded as it progresses its clinical trial in Graft-versus-Host-Disease (GvHD) towards a major value catalyst and advances other disease indications in its development pipeline.

The R&D Tax Incentive is an important Australian Government program that refunds up to 45% of eligible expenditure on research and development.

**Ends**

**CONTACTS:** Dr Ross Macdonald, CEO: Tel: 0412 119343; email [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Daniel Paproth, Australia Media Contact, +61 (0)421 858 982 , [daniel.paproth@mcpartners.com.au](mailto:daniel.paproth@mcpartners.com.au)  
Laura Bagby, U.S. Media Contact, 312-448-8098, [lbagby@6degreespr.com](mailto:lbagby@6degreespr.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.